Drugs / LY3972406
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06176768 | Dec 2023 → Apr 2025 | psoriasis | Eli Lilly and Company | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3972406 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06176768 ↗ |
| Route | Oral | “Administered orally” NCT06176768 ↗ |